Preclot is a prodrug that is used to treat blood clots. The irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets suppresses platelet activation and aggregation. Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses. On the first day, repeated 75 mg doses decrease ADP-induced platelet aggregation, and inhibition achieves a stable state between Days 3 and 7.
Acute Coronary Syndrome: Start clopidogrel with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily in individuals who need an antiplatelet effect within hours. It will take several days to establish an antiplatelet effect if you start it without a loading dosage.
75 mg once a day orally without a loading dose for recent MI, recent stroke, or established peripheral arterial disease.
It's taken by mouth, with or without meals.
NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole): Increases the risk of bleeding. Avoid taking omeprazole or esomeprazole at the same time.
Repaglinide (substrates for CYP2C8): Clopidogrel should not be taken with Repaglinide since it raises Repaglinide plasma level.
Preclot should not be used if you have any of the following conditions: Hypersensitivity to the medicine or any of the product's components. Peptic ulcer or cerebral hemorrhage are examples of active pathological bleeding.
Preclot is a medication that is generally well tolerated.
Bleeding, diarrhea, gastrointestinal discomfort, hemorrhage, and skin responses are all common adverse effects.
Acquired hemophilia, anemia, angioedema, arthralgia, arthritis, and bone marrow abnormalities are all rare adverse effects.
In pregnant women, there are no sufficient and well-controlled trials. It should only be used during pregnancy if absolutely necessary. Preclot is not known to be excreted in human breast milk. Considering the medicine's value to the mother, a decision should be taken whether to quit nursing or discontinue the drug.
Because it is a prodrug, genetic polymorphisms in CYP2C19 (a poor metabolizer) and medicines that inhibit CYP2C19, such as Omeprazole and Esomeprazole, hinder metabolism to its active metabolite. Clopidogrel's antiplatelet action may be reduced if it is taken with certain medications or if you have a CYP2C19 poor metabolizer.
The risk of bleeding may increase since it inhibits platelet aggregation during the platelet's whole lifetime (7-10 days). Platelet transfusions given within 4 hours of the loading dosage or 2 hours of the maintenance dose may be less efficient in restoring hemostasis.
Preclot discontinuation raises the risk of cardiovascular events. 5 days before an elective procedure with a high risk of bleeding, stop taking it. As soon as hemostasis is achieved, resume Clopidogrel.
TTP (Thrombotic Thrombocytopenic Purpura) is a type of thrombocytopenic purpura that requires immediate treatment, including plasmapheresis (plasma exchange).
Patients on clopidogrel or who have a history of hypersensitivity to other thienopyridines have suffered rash, angioedema, or hematologic reactions.
In a dry environment, keep the temperature below 30°C. Protected from the sun's rays. Do not allow yourself to become frozen. Keep out of children's reach.